Core Viewpoint - C21 Investments Inc. plans to initiate a normal course issuer bid (NCIB) to repurchase up to 5,898,596 common shares, approximately 5% of its outstanding shares, to enhance long-term shareholder value [1][4]. Group 1: NCIB Details - The NCIB will commence on December 9, 2025, and conclude on December 9, 2026, allowing the company to buy shares on the open market at prevailing market prices [2]. - The company may purchase up to 2% of its issued and outstanding common shares over any 30-trading day period under the NCIB [3]. - Purchases will be funded with cash on hand, and the timing and amount of purchases will depend on market conditions [2][4]. Group 2: Previous NCIB Performance - The company recently completed a previous NCIB, which allowed for the repurchase of up to 6,002,390 common shares, resulting in the cancellation of 224,000 shares at an average price of approximately C$0.20 per share [5]. Group 3: Company Overview - C21 Investments Inc. is a vertically integrated cannabis company engaged in the cultivation, processing, and distribution of cannabis and hemp-derived products in the U.S. [6]. - The company focuses on value creation through strategic acquisitions and integration of retail, manufacturing, and distribution assets, leveraging high-growth potential in branded consumer packaged goods [6].

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - STUBDecember 05, 2025 2:58 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with Stu ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Issues - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Investors who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm is preparing to seek recovery of investor losses [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering substantial amounts for investors [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Performance - Western Alliance Bancorporation disclosed a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 30, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Synopsys' management made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [5]. - Specific allegations include the negative impact of Synopsys' focus on artificial intelligence customers on its Design IP business and the misleading nature of positive statements made by the defendants regarding the company's prospects [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of CarMax, Inc. to secure counsel before the January 2, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from June 20, 2025, to November 5, 2025 [2][6]. Group 1: Class Action Details - Investors who purchased CarMax securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 2, 2026 [4][6]. - The lawsuit alleges that CarMax's management made materially false statements regarding the company's growth prospects, which were based on temporary market conditions rather than sustainable business performance [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing shareholder interests [5].

AVTR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AVTRDecember 05, 2025 2:15 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (t ...

MLTX FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action - MLTXDecember 05, 2025 2:12 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 20 ...

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the December 29, 2025 deadline for lead plaintiff applications [1]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information via the provided link or contact the firm directly for further details [3][6]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its success in securities class action settlements, including a notable recovery of over $438 million for investors in 2019 [4]. - Investors are advised that until a class is certified, they are not represented unless they retain counsel, and they have the option to remain absent from the class [7].

JHX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages James Hardie Industries plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - JHXDecember 05, 2025 1:45 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of James Hardie Industries plc (NYSE: JHX) between May 20, 2025 through August 18, 2025, bo ...